Table 3 Potential biomarkers for precision treatment with Akt inhibitors

PTEN mutation or deficiency

Prostate cancer, breast cancer, endometrial cancer, glioblastoma, thyroid cancer, etc.

[235]

PIK3CA mutation

Breast cancer, ovarian cancer, colorectal cancer, lung cancer, endometrial carcinoma, cervical adenocarcinoma, glioma, head and neck cancer, etc.

[234]

Akt1 E17K

Breast cancer, ovarian cancer, endometrial carcinoma, meningioma, etc.

[232, 240]

Activating Akt1/2 indels

Breast cancer, prostate cancer, clear cell renal cancer, etc.

[239]

ARID1A/B mutations or deficiency

Gastric, ovarian and endometrioid carcinoma, medulloblastoma

[245,246,247]

SF3B1 mutation

Myelodysplastic/myeloproliferative neoplasms, melanoma, breast cancer, pancreatic cancer, prostate cancer, AML, etc.

[254, 255]

NPM1 mutation

AML

[257]

NM23-H1

Breast cancer, melanoma, etc.

[248]

CBL mutation

Myeloid neoplasmas

[249]

BTK mutation or deficiency

Follicular lymphoma

[253]

GPS2 mutation

Breast cancer, medulloblastoma

[250,251,252]

CDH1 mutation or deficiency

Gastric cancer, breast cancer, prostate cancer, colorectal cancer, ovarian cancer, etc.

[261, 262]

SMAD4 mutation

Colorectal cancer, pancreatic cancer

[269, 270]

GAB2 mutation or amplification

Hematological malignancies, ovarian cancer, lung cancer, neuroblastoma, melanoma, breast cancer

[264,265,266,267,268]